Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results
| Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Companys Highest Revenue Quarter | ||
| Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating Expense Containment | ||
| Restructuring Exceeding Full-Year Savings… |
